Critical points in the management of EGFR -mutated non-small cell lung cancer.

Competing Interests: Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-269/coif). CG in the past two years has received the funding listed below from the following sources as an advisory board member, Speaker bureau member or consultant: Amgen, Astra Zeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GSK, Karyopharm, Menarini, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda. The other author has no conflicts of interest to declare.